share_log

TCR2 Therapeutics Analyst Ratings

TCR2 Therapeutics Analyst Ratings

TCR2治疗分析师评级
Benzinga Analyst Ratings ·  2023/01/05 04:34
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
01/05/2023 90.48% EF Hutton → $2 Initiates Coverage On → Hold
11/21/2022 1138.1% HC Wainwright & Co. $14 → $13 Maintains Buy
11/08/2022 90.48% SVB Leerink $3 → $2 Maintains Market Perform
05/19/2022 1233.33% HC Wainwright & Co. $19 → $14 Maintains Buy
03/23/2022 185.71% SVB Leerink $7 → $3 Maintains Market Perform
01/19/2022 376.19% Goldman Sachs $28 → $5 Downgrades Buy → Neutral
01/13/2022 1709.52% HC Wainwright & Co. $25 → $19 Maintains Buy
11/10/2021 566.67% SVB Leerink $8 → $7 Maintains Market Perform
10/21/2021 661.9% SVB Leerink $18 → $8 Downgrades Outperform → Market Perform
09/20/2021 2661.9% Truist Securities $40 → $29 Maintains Buy
09/20/2021 2280.95% HC Wainwright & Co. $37 → $25 Maintains Buy
09/17/2021 947.62% Wedbush $45 → $11 Downgrades Outperform → Neutral
08/06/2021 2852.38% SVB Leerink $34 → $31 Maintains Outperform
06/24/2021 2757.14% Goldman Sachs → $30 Initiates Coverage On → Buy
03/11/2021 3138.1% SVB Leerink $41 → $34 Maintains Outperform
12/14/2020 3423.81% HC Wainwright & Co. $32 → $37 Maintains Buy
11/30/2020 3519.05% Roth Capital $35 → $38 Maintains Buy
08/21/2020 — Mizuho Initiates Coverage On → Buy
08/13/2020 3709.52% Truist Securities → $40 Initiates Coverage On → Buy
08/13/2020 2947.62% HC Wainwright & Co. $33 → $32 Maintains Buy
08/12/2020 2280.95% SVB Leerink $26 → $25 Maintains Outperform
08/12/2020 3233.33% Piper Sandler → $35 Initiates Coverage On → Overweight
07/27/2020 3233.33% Roth Capital $16 → $35 Upgrades Neutral → Buy
07/27/2020 3042.86% HC Wainwright & Co. $19 → $33 Maintains Buy
11/04/2019 1709.52% HC Wainwright & Co. → $19 Initiates Coverage On → Buy
05/31/2019 1423.81% Roth Capital → $16 Initiates Coverage On → Neutral
03/11/2019 2566.67% Wedbush → $28 Initiates Coverage On → Outperform
03/11/2019 3423.81% BMO Capital → $37 Initiates Coverage On → Outperform
03/11/2019 2852.38% Jefferies → $31 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
01/05/2023 90.48% EF Hutton → $2 开始承保 →保留
11/21/2022 1138.1% HC Wainwright公司 $14 → $13 维护 买
11/08/2022 90.48% SVB Leerink $3 → $2 维护 市场表现
05/19/2022 1233.33% HC Wainwright公司 $19 → $14 维护 买
03/23/2022 185.71% SVB Leerink $7 → $3 维护 市场表现
01/19/2022 376.19% 高盛 $28 → $5 评级下调 购买→中性
01/13/2022 1709.52% HC Wainwright公司 $25 → $19 维护 买
11/10/2021 566.67% SVB Leerink $8 → $7 维护 市场表现
10/21/2021 661.9% SVB Leerink $18 → $8 评级下调 跑赢→市场表现
09/20/2021 2661.9% Truist证券 $40 → $29 维护 买
09/20/2021 2280.95% HC Wainwright公司 $37 → $25 维护 买
09/17/2021 947.62% 韦德布什 $45 → $11 评级下调 跑赢→中性
08/06/2021 2852.38% SVB Leerink $34 → $31 维护 跑赢大盘
06/24/2021 2757.14% 高盛 → $30 开始承保 →购买
03/11/2021 3138.1% SVB Leerink $41 → $34 维护 跑赢大盘
12/14/2020 3423.81% HC Wainwright公司 $32 → $37 维护 买
11/30/2020 3519.05% 罗斯资本 $35 → $38 维护 买
08/21/2020 — 瑞穗 开始承保 →购买
08/13/2020 3709.52% Truist证券 → $40 开始承保 →购买
08/13/2020 2947.62% HC Wainwright公司 $33 → $32 维护 买
08/12/2020 2280.95% SVB Leerink $26 → $25 维护 跑赢大盘
08/12/2020 3233.33% 派珀·桑德勒 → $35 开始承保 →超重
07/27/2020 3233.33% 罗斯资本 $16 → $35 升级 中性→购买
07/27/2020 3042.86% HC Wainwright公司 $19 → $33 维护 买
11/04/2019 1709.52% HC Wainwright公司 → $19 开始承保 →购买
05/31/2019 1423.81% 罗斯资本 → $16 开始承保 →中性
03/11/2019 2566.67% 韦德布什 → $28 开始承保 →跑赢大盘
03/11/2019 3423.81% 蒙特利尔银行资本 → $37 开始承保 →跑赢大盘
03/11/2019 2852.38% 杰富瑞 → $31 开始承保 →购买

What is the target price for TCR2 Therapeutics (TCRR)?

TCR2治疗(TCRR)的目标价格是多少？

The latest price target for TCR2 Therapeutics (NASDAQ: TCRR) was reported by EF Hutton on January 5, 2023. The analyst firm set a price target for $2.00 expecting TCRR to rise to within 12 months (a possible 90.48% upside). 7 analyst firms have reported ratings in the last year.

EF Hutton于2023年1月5日报道了TCR2治疗公司(纳斯达克：TCRR)的最新目标价。这家分析公司将目标价定为2.00美元，预计TCRR将在12个月内升至(可能上涨90.48%)。去年有7家分析公司公布了评级。

What is the most recent analyst rating for TCR2 Therapeutics (TCRR)?

TCR2治疗公司(TCRR)的最新分析师评级是什么？

The latest analyst rating for TCR2 Therapeutics (NASDAQ: TCRR) was provided by EF Hutton, and TCR2 Therapeutics initiated their hold rating.

对TCR2治疗公司(纳斯达克代码：TCRR)的最新分析师评级是由EF Hutton提供的，TCR2治疗公司启动了他们的持有评级。

When is the next analyst rating going to be posted or updated for TCR2 Therapeutics (TCRR)?

TCR2治疗公司(TCRR)的下一次分析师评级将于何时发布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TCR2 Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TCR2 Therapeutics was filed on January 5, 2023 so you should expect the next rating to be made available sometime around January 5, 2024.

分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与TCR2治疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。TCR2治疗公司的上一次评级是在2023年1月5日提交的，所以你应该预计下一次评级将在2024年1月5日左右的某个时候提供。

Is the Analyst Rating TCR2 Therapeutics (TCRR) correct?

分析师对TCR2治疗公司(TCRR)的评级正确吗？

While ratings are subjective and will change, the latest TCR2 Therapeutics (TCRR) rating was a initiated with a price target of $0.00 to $2.00. The current price TCR2 Therapeutics (TCRR) is trading at is $1.05, which is within the analyst's predicted range.

虽然评级是主观的，并将发生变化，但最新的TCR2治疗(TCRR)评级是以0.00美元至2.00美元的目标价启动的。目前TCR2治疗公司(TCRR)的交易价格为1.05美元，在分析师的预测范围内。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发